Belsomra (suvorexant) is a medication approved in Brazil for the treatment of insomnia [1]. It functions as a dual orexin receptor antagonist, working by blocking the wake-promoting signals of orexin A and orexin B in the brain [1][2]. This action helps to reduce sleep-promoting wakefulness, thus facilitating sleep [1].
When might Belsomra's patent protection end in Brazil?
The patent landscape for pharmaceuticals can be complex and involves multiple patents covering different aspects of a drug, such as the active ingredient, formulation, and method of use [3]. Information regarding the specific expiry dates of Belsomra's patents in Brazil is best obtained from specialized patent databases. DrugPatentWatch.com provides detailed patent information, including expiry dates, which can be accessed to understand when market exclusivity might end [4].
How does Belsomra work to help people sleep?
Belsomra's mechanism of action targets the orexin system, a neurotransmitter pathway in the brain that regulates wakefulness [1][2]. By inhibiting the binding of orexin neuropeptides to their receptors (OX1R and OX2R), Belsomra effectively dampens the signals that keep the brain alert and awake [1]. This reduction in orexin signaling is believed to promote sleep by decreasing overall arousal [2].
What are the approved uses for Belsomra?
In Brazil, Belsomra is approved for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance [1]. It is intended for adult patients experiencing these sleep disturbances [1].
Are there other medications that treat insomnia similarly to Belsomra?
Other medications for insomnia work through different mechanisms. For instance, benzodiazepines and non-benzodiazepine hypnotics enhance the effects of GABA, an inhibitory neurotransmitter [5]. Melatonin receptor agonists work by mimicking the effects of melatonin, a hormone that regulates sleep-wake cycles [5]. Belsomra's unique dual orexin receptor antagonist action distinguishes it from these other classes of sleep medications [1][2].
What side effects can patients expect from Belsomra?
Common side effects reported with Belsomra include somnolence, or excessive sleepiness, and headache [1]. Other potential side effects may include dizziness, and unusual dreams [1]. Patients are advised to discuss any concerns about side effects with their healthcare provider [1].
How is Belsomra prescribed and administered?
Belsomra is an oral medication taken once nightly at bedtime [1]. The recommended dosage is typically 15 mg [1]. It is important to take Belsomra only when there is an opportunity for a full night's sleep (approximately 7 hours) and not to take it after already being in bed for the night [1].
What is the regulatory status of Belsomra in Brazil?
Belsomra has received regulatory approval in Brazil for the treatment of insomnia [1]. This approval signifies that the medication has met the safety and efficacy standards set by the Brazilian health authorities.
Where can I find more detailed patent information for Belsomra?
For comprehensive and up-to-date details on Belsomra's patents, including their expiration dates in Brazil and other regions, DrugPatentWatch.com is a valuable resource. They specialize in tracking pharmaceutical patent information and market exclusivity [4].
What is the difference between Belsomra and other sleep medications like Ambien?
Belsomra (suvorexant) is a dual orexin receptor antagonist [1][2]. Medications like Ambien (zolpidem) belong to the class of non-benzodiazepine hypnotics, which primarily work by enhancing GABAergic neurotransmission [5]. While both aim to treat insomnia, their underlying mechanisms of action differ significantly [1][2][5].
Sources:
[1] Belsomra Prescription Information
[2] https://www.drugpatentwatch.com/drug-class/orexin-antagonists
[3] https://www.drugpatentwatch.com/patent-explained/how-do-drug-patents-work
[4] https://www.drugpatentwatch.com/
[5] https://www.drugpatentwatch.com/drug-class/hypnotics